Small Cap Wrap – Science Group, Diaceutics, Cloudcall and more…

Further media reports that Dr Martens, the British Boot brand is planning an IPO on the LSE.  It is currently owned by PE group, Permira who  is expected to sell down its stake at the IPO.  March 2020 YE the group had revenues of £672m and EBITDA of £184m.  Deal size TBC. 

Upon Admission to AIM, Nightcap will acquire The London Cocktail Club Limited (the “London Cocktail Club”)

11 Jan 2021

@HybridanLLP

 

*A corporate client of Hybridan LLP

 

Dish of the day

No joiners today

Off the menu

No leavers today

What’s cooking in the IPO kitchen?

Further media reports that Dr Martens, the British Boot brand is planning an IPO on the LSE.  It is currently owned by PE group, Permira who  is expected to sell down its stake at the IPO.  March 2020 YE the group had revenues of £672m and EBITDA of £184m.  Deal size TBC. 

Upon Admission to AIM, will acquire The London Cocktail Club Limited (the “London Cocktail Club”), which is an award winning independent operator of ten individually themed cocktail bars in nine London locations and one location in Bristol. Offer TBC Due mid Jan.

HSS Hire Group, HSS.L transfer from Main to Aim. Mkt Cap c. £70m. Recently raised £52.6m. Leading supplier of tool and equipment for hire in the United Kingdom and Ireland and has provided equipment hire services in the United Kingdom for more than 60 years, primarily focusing on the B2B market.  Due 14 Jan.

VH Global Sustainable Energy Opportunities plc, a closed-ended investment Company focused on making sustainable energy infrastructure investments, today announces intends to launch an initial public offering  of shares on the Official List (Premium) of the Main Market of the London Stock Exchange.  Due by Early Feb.

Banquet Buffet

Science Group 315p  £129.6m ()

Trading, Business and Board Update from the  international consulting services group supporting the entire product innovation lifecycle.  

Group revenue for the year is now anticipated to be in the order of £73 million (2019: £57.2 million).  While the Board took the opportunity during the second half of the year to increase investment in infrastructure and personnel, early indications are that, subject to audit, the Group’s adjusted operating profit for the year ended 31 December 2020 will exceed the previously upgraded expectations of £10 million (2019: £6.7 million).

After almost 7 years with the Group, Rebecca Archer, Group Finance Director, has advised the Board of her intention to resign to take up a new role.  Sameet (SAM) Vohra has accepted the position of Chief Financial Officer Designate. Sam qualified as a Chartered Accountant with KPMG and has gained considerable experience in senior finance leadership roles in UK listed international businesses, including Group Financial Controller at and Group Director of Finance at , the FTSE 250 precision engineering company. Most recently, he was Interim Group Finance Director at during their financial restructuring.

Since the acquisition in 2019, the restructuring and turnaround of Frontier has been very successful, resulting in an excellent performance in 2020. Frontier is now a strongly profitable technology business with a market leading position. Confirmed orders at the start of 2021 are very healthy and shipments in the first part of the year may be supply constrained.

 

Diaceutics 148.5p  £124.8m ()

Trading update from the data analytics and end-to-end services provider enabled by DXRX – its –proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics.   Despite the challenges presented in the year due to the Covid-19 pandemic, Diaceutics has progressed its strategy and the Group’s revenue and adjusted EBITDA for the year to 31 December 2020 are expected to be approximately £12.6m (2019: £13.4m) and £0.5m (2019: £2.2m) respectively, with EBITDA breakeven. This is ahead of revised market expectations. 

The Group has a strong closing cash position of £25.3m (2019: £11.7m) which includes the funds from the £20.5m share placing, completed in June 2020. 

Significant progress has also been made on ‘DXRX – The Diagnostic Network®’, the Company’s proprietary Diagnostic Network platform for precision medicine, since its successful launch on schedule on 28 October 2020 with:

· 19 of the Company’s top 30 Pharma clients engaged with the platform to explore their precision medicine needs and eight client projects now confirmed for delivery via the platform in H1 2021; and

· 68 leading cancer laboratories and diagnostic companies have been successfully brought directly online to support marketplace collaborations.

 

113.5p  £44.1m ()

The integrated communications company that provides unified communications and contact centre software that tightly integrates with Customer Relationship Management platforms, launches its second integration with The Access Group, further strengthening the partnership and footprint within the recruitment sector.

The new integration, which comes after Access Profile, brings together CloudCall’s powerful integrated communications software with Access Recruitment CRM, enhancing the suite of recruitment CRM products and services within The Access Group’s impressive portfolio.

 Access Recruitment Software is trusted by more than 200 of the top UK’s recruitment agencies including Adecco, Alexander Mann, and .

 

1.45p  £8.9m ()

The social media and marketing group announced that trading in the second half of 2020 has been ahead of both management expectations and the corresponding period from the prior year. These H2 2020 results mark encouraging progress for Brave Bison, although the Board continues to manage costs carefully in what remains an uncertain economic environment. For the six-month period to 31 December 2020 (unaudited):

 ● Adjusted EBITDA (before exceptional items and share based payments)1 is expected to be not less than positive £500k, compared to negative £658k for H2 2019 and ahead of the expectation, reported in the Company’s Interim Results announced in July 2020, that the Company would become EBITDA breakeven on the same basis during H2 2020.

 ● Net cash has increased by £634k from £2.1m in June 2020 to £2.7m as at 31 December 2020.

 ● Revenue is expected to be not less than £7.2m, an increase of 7% on H2 2019.

 

800p  £104.5m ()

The providers of management and resources to the fire and emergency services in the Middle East  announces that Martin Gilbert, Peter McKellar, various associates and funds managed by Toscafund Asset Management, a multi asset fund manager, have, in aggregate, acquired a minority stake of 29.8% of the issued share capital of the Company at 475 pence per share, which is approximately the estimated net asset value per share, from a number of institutional shareholders and the Board.

 

62.5p  £86.5m ()

The specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the grant of a key patent for Chronocort® (modified release hydrocortisone) by the European Patent Office. EP2814469 , entitled “Hydrocortisone controlled-release formulation”, is a patent disclosing and claiming the composition of matter and medical use of Chronocort® for the treatment of patients with the rare diseases congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI). The patent provides in-market European protection until 2033 in all designated states of the European Patent Convention. The equivalent patents from the same family are already granted in the UK, Canada, Mexico, New Zealand, Japan, Australia, Israel, South Africa, South Korea and in the US. 

The Marketing Authorisation Application (MAA) for Chronocort® as a treatment for adolescents and adults with CAH is under review by the European Medicines Agency (EMA) following submission of the MAA dossier in December 2019. The MAA was subsequently validated and accepted for review by the EMA in April 2020 and the outcome of the EMA review is anticipated during Q1 2021.

 

Frontier IP 66p  £36.3m ()

The specialist in commercialising intellectual property, notes an announcement from portfolio company Elute Intelligence Holdings Limited that it has successfully raised £250,000 through its first equity funding round.

The investment, made by private investors in return for a 10 per cent equity stake, values the Company at £2.5 million post-money, and Frontier IP’s holding of 41 per cent at £1.0 million.

Proceeds from the fundraising will be used to support Elute’s recently launched Patent Reader and development of an enterprise search tool based on the same underlying technology, which uses forensic linguistics to speed searches through unstructured document datasets.

 

Intuitive Investments 22.75p  £9.2m ()

The closed-end investment company focussed on the life sciences sector, announces a pre-IPO investment of £1 million by way of unsecured convertible loan notes in Light Science Technologies Holdings Limited. LST is intended to become the holding company for a UK based light technology company, with initial applications in the controlled agriculture environment sector and a longer-term development application in non-invasive medical diagnostics. 

LST is IIG’s first investment from its pipeline of opportunities, following its successful IPO and Admission to AIM in December 2020.

 

Draper Esprit 675p  £938.4m ()

The venture capital firm investing in and developing high growth digital technology businesses, today provides an update on recent developments in its portfolio.

 Key highlights are as follows:

· Draper Esprit continues to experience strong business momentum

· Delivering on its stated objective to deploy further capital by leading rounds in high growth technology investments at Series B onwards

· Investments comprise a mix of new portfolio companies and follow on into high growth opportunities in the existing portfolio

· £56 million invested in 11 investments since 30th September 2020 (£32 million invested to half year)

 

Group 7p  £3.45m ()

Further to its announcement of 7 December 2020, Tricorn Group plc, the AIM listed tube manipulation specialist, announces that the stocktakes conducted at both of its UK sites, Malvern and West Bromwich, during December 2020 produced a modest gain of approximately 2 per cent. of gross inventory. The Board considers that this was an encouraging indication supporting the integrity of the ongoing margins in the Company’s current financial year.

A further announcement will be made later this month regarding the Group’s trading in the first quarter to 31 December 2020.

 

Head Chef

Derren Nathan

0203 764 2344

[email protected]

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II              Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.



Source link

Add a Comment